Evidence map›Paper›PMID 42078615›Full record

ArticleAnnals of medicine and surgery (2012)2026

Vykat XR (diazoxide choline-extended release): a new FDA-approved treatment for hyperphagia in Prader-Willi syndrome.

Prakriti Pokhrel, Hidhaya S Noorul, Laraib Fatima, Aakash Kumar, Amrah Abdul Samad, Gerardo F Ferrer

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Prakriti PokhrelDepartment of Psychiatry, Kathmandu Medical College and Teaching Hospital, Kathmandu, Nepal.ORCID https://orcid.org/0000-0002-9455-2249
Hidhaya S NoorulStanley Medical College, Chennai, India.ORCID https://orcid.org/0009-0002-2927-2192
Laraib FatimaDow University of Health Sciences, Karachi, Pakistan.ORCID https://orcid.org/0009-0000-0054-230X
Aakash KumarBahria University Health Sciences Campus, Karachi, Pakistan.ORCID https://orcid.org/0009-0008-9524-3086
Amrah Abdul SamadDow University of Health Sciences, Karachi, Pakistan.ORCID https://orcid.org/0009-0004-3796-8389
Gerardo F FerrerDepartment of Psychiatry, Larkin Community Hospital, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On March 27, 2025, the U.S. Food and Drug Administration (FDA) approved Vykat XR (diazoxide choline-extended release tablets) for the treatment of hyperphagia in individuals aged 4 years and older with Prader-Willi Syndrome (PWS). This marks the first FDA-approved pharmacologic therapy targeting hyperphagia in this population, addressing a long-standing unmet need and offering new hope for patients, caregivers, and clinicians.

Indexed as

diazoxide cholinehyperphagiaPrader-Willi syndromeVykat XR

Identifiers

PMID42078615
PMCPMC13132293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.